High implied probabilities for no new COVID variant of concern before 2027 reflect the absence of any SARS-CoV-2 lineage meeting WHO or ECDC VOC criteria in recent months, with only variants under monitoring such as BA.3.2, XFG, and NB.1.8.1 circulating at low public health risk. Surveillance through June 2026 shows these strains driving typical seasonal activity without evidence of substantially greater transmissibility, immune escape, or severity that would trigger reclassification. Ongoing genomic tracking by agencies like the CDC and ECDC has not identified emerging candidates with the required impact on vaccines, treatments, or hospital systems. With roughly five months remaining, the lack of rapid evolution or concerning signals supports trader consensus that current subvariants will remain stable through year-end.